Actively Recruiting
A Muscle-brain Interplay Study in Neurological Disorders
Led by Istituti Clinici Scientifici Maugeri SpA · Updated on 2026-03-17
150
Participants Needed
4
Research Sites
83 weeks
Total Duration
On this page
Sponsors
I
Istituti Clinici Scientifici Maugeri SpA
Lead Sponsor
U
University of Roma La Sapienza
Collaborating Sponsor
AI-Summary
What this Trial Is About
Despite the improvements in life expectancy, neurodegenerative diseases (NDGs) have become the most dreaded disorders of older people. Aged brains show characteristic changes that are linked to neurodegeneration raising the question of whether these hallmarks represent the harbingers of NDGs. Lifestyle factors including, in particular physical exercise, have given particular attention to factors associated to movement issue as ones of the major factors in modulating the risk of developing NDGs, emphasizing the interest in the muscle-brain axis. Indeed, one of the crucial systems severely affected in several neuromuscular diseases is the loss of effective connection between muscle and nerve, and the neuromuscular junction (NMJ) represents the critical region at the level of which the two entities communicate. Even if controversy exists on whether pathological events beginning at the NMJ precede or follow loss of motor units, some recent data highlight as NGDs (e.g. Amyotrophic Lateral Sclerosis, Alzheimer's Disease, and Parkinson's Disease) and Aging share some common pathologic features such as the loss of fast-twich fiber, a decreased number of synaptic vesicles and sarcopenia giving evidence supports the notion that NMJ dismantlement can occur independently from motor neuron degeneration and may represent an early pathogenic signature of muscle-nerve communication defects. The M-Brain project is an observational, analytical case-control study that will apply a new approach to interpret data underling the NMJ dismantlement in NDGs patients by comparing their clinical and biological information with data obtained from people who have had a so called "good aging" and those who have had a "bad aging". The study will collect data useful to identify potential predisposing or risk factors for the subsequent development of a NDGs or able to predict the phenotype traiectories of selected pathologies with differerent movement levels. The combination of a muscular and neurological phenotyping and a biological characterization combining biomarkers, miRNA and extracellular vesicle (EV) assessments will allow to better identify the determinants of muscle-brain cross-talk that can then be used as potential indicators for the definition of critical morphological and functional components involved in aging and some NGDs. The project then will aim to identify phenotyope trajectories of patients giving particular attention to the brain-muscle axis and movement issues in order to provide information useful for future clinical strategies able to minimaze risk/predisponent Factors.
CONDITIONS
Official Title
A Muscle-brain Interplay Study in Neurological Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 60 years or older
- For Good aging group: Frailty Index below pathological cut-off (>0.25)
- For Good aging group: No general cognitive impairment (MMSE > 24 points)
- For Good aging group: No diagnosis of sarcopenia
- For Bad aging group: Diagnosed with one of the following: Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD), Alzheimer's Disease (AD), severe acquired brain injury with sarcopenia, mild cognitive impairment or subjective memory complaint without neurological diseases or sarcopenia, or sarcopenia without cognitive deficits or neurological diseases
You will not qualify if you...
- Unable to provide informed consent
- Presence of severe and/or acute comorbidities such as uncontrolled diabetes, heart failure, or cancer
- Previous neurological or psychiatric disorders affecting cognition
- Uncontrolled systemic diseases or history of traumatic brain injury
- For participants with AD, PD, or ALS: history of epilepsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Universita degli Studi di Catania
Catania, Italy, 95131
Active, Not Recruiting
2
IRCCS Centro Neurolesi Bonino Pulejo
Messina, Italy, 98123
Actively Recruiting
3
Istituti Clinici Scientifici Maugeri IRCCS, Milan Institute
Milan, Italy, 20138
Actively Recruiting
4
University of Roma La Sapienza
Roma, Italy, 00185
Active, Not Recruiting
Research Team
C
Christian Lunetta, MD
CONTACT
D
Davide Sattin, PsyD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here